This report examines the market for vaccines used in humans to previous various types of disease. It covers only commercialized vaccines and developmental vaccines for diseases that are already vaccine-preventable; it does not cover emerging vaccines for diseases that are not currently vaccine-preventable, such as Alzheimer's disease, diabetes, Ebola infection, Epstein-Barr virus (EBV) infection, ETEC infection, heart attach, Helicobacter pylori infection, multiple sclerosis, Parkinson's disease, West Nile virus (WNV) infection, etc.; vaccines that address these and other not-yet-vaccine-preventable conditions are discussed in Kalorama's new report, “What's Next in Vaccines.”
The vaccine industry has seen changes in the past year, and these are covered in this report Vaccines 2012: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry. The high growth rates and successful launch of several products recently have kept interest in the global vaccine market high. The global market for vaccines experienced strong growth through 2011 and this is expected to continue through the forecast period. Growth is being fueled by new product introductions and rising usage in all regions.
Included in this report are current market size and forecast for the following vaccines:
Combinations Hepatitis HIB MMR Pneumococcal Poliovirus Varicella Other Pediatric
Kalorama has expanded the global perspective of this report in this edition, including estimates of vaccine sales (pediatric and adult segments) in the following regions:
Despite ongoing improvements in pediatric vaccination, it is estimated that at least two million children die each year from diseases that could have been prevented by already existing vaccines. This problem is most significant in low income countries, with the health disparity between rich and poor countries resulting in average life spans of about 77 and 52 years, respectively. In addition to this high death toll, millions more suffer disability and illness because they have not been immunized. Adult immunization is an important, but frequently overlooked, part of patient care. Vaccination programs typically focus on children, yet adults in industrialized countries are more likely to die as a result of vaccine-preventable diseases than are children.
Key issues in the global vaccine market today include product safety, refusal to immunize, supply shortages, the use of vaccines to prevent pandemics and address bioterrorism, and innovations in vaccine delivery systems.
Vaccination protects not only individuals, but also entire communities from diseases spread by person-to-person transmission.For example, vaccination can prevent about 50% of deaths from pneumococcal disease and 80% of deaths from influenza-related complications in the elderly. Pharmacoeconomic studies have demonstrated the value of influenza and pneumococcal vaccines; however, immunization rates for these diseases continue to be low in the elderly populations.
This report includes profiles of the key players in vaccines, including: